Drug Trial Radar · NCT04875195
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jun 7, 2021
Primary completion
Dec 14, 2023
Study completion Oct 13, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
Conditions
- Hodgkin's Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions
PembrolizumabBiological
Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Per Lugano Classification as Assessed by InvestigatorTime frame: Up to approximately 30 months
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site
Torrance, California
Tulane Medical Center ( Site 0110)
New Orleans, Louisiana
Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)
Annapolis, Maryland
Hospital Erasto Gaertner ( Site 1703)
Curitiba, Paraná, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1701)
Barretos, São Paulo, Brazil
Cross Cancer Institute ( Site 0207)
Edmonton, Alberta, Canada
Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304)
Hradec Králové, Czechia
Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302)
Brno, Brno-mesto, Czechia
Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303)
Prague, Praha 10, Czechia
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0401)
Dijon, Cote-d Or, France
Gustave Roussy ( Site 0402)
Villejuif, Île-de-France Region, France
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503)
Naples, Italy
Fondazione IRCCS Policlinico San Matteo ( Site 0509)
Pavia, Lombardy, Italy
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0507)
Palermo, Sicily, Italy
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-Oddzial Hematologii i Transplantacji S
Poznan, Greater Poland Voivodeship, Poland
Pratia MCM Krakow ( Site 0064)
Krakow, Lesser Poland Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0063)
Gdansk, Pomeranian Voivodeship, Poland
The National Medico-Surgical Center N.I. Pirogov ( Site 0801)
Moscow, Moscow, Russia
Moscow City Clinical Hospital S.P. Botkin ( Site 0803)
Moscow, Moscow, Russia
Almazov National Medical Research Centre ( Site 0807)
Saint Petersburg, Sankt-Peterburg, Russia
Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 0902)
Centurion, Gauteng, South Africa
Wits Clinical Research ( Site 0904)
Johannesburg, Gauteng, South Africa
Groote Schuur Hospital ( Site 0906)
Cape Town, Western Cape, South Africa
Ankara University Department of Hematology, Clinical Research Unit ( Site 1101)
Ankara, Turkey (Türkiye)
Ege University Medicine of Faculty ( Site 1105)
Bornova, İzmir, Turkey (Türkiye)
CNPE Regional Center of Oncology ( Site 1305)
Kharkiv, Kharkiv Oblast, Ukraine
National Cancer Institute ( Site 1303)
Kyiv, Kyivska Oblast, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.